RJ Hamster
Four Analysts Say the Market Is Missing This Story…
| Unsubscribe A message from Market Jar, Inc On Behalf of Cardiol TherapeuticsDear Trader,When a doctor from the world-renowned Mayo Clinic leadership presents your clinical data at a global cardiology event, people pay attention.That just happened for this under-the-radar biotech.Their trial delivered the first drug ever to show structural reversal of heart damage in myocarditis, a disease with zero approved treatments.The result? A meaningful reduction in left ventricular mass with 99% confidence—an achievement cardiologists would immediately embrace.And this is just the beginning.Their Phase 3 trial is successfully enrolling across 20 major cardiac centers, targeting a billion-dollar pericarditis market currently dominated by a single $270,000/year injectable drug.But the real story is what comes next.Their next-generation heart failure program enters human trials, aiming at a condition that affects 6.7 million Americans and where blockbuster drugs routinely generate billions in annual revenue.Wall Street analysts are covering this story and rating it a buy.Average target: 700% upside from recent levels.Yet the stock is still trading as if it were a small-cap with mere potential, rather than a late-stage biotech with breakthrough human data and a fully funded path to commercialization.That disconnect won’t last forever.Get the full investor report before the rest of the world figures this out. Today’s editorial pick for you3 Strong Growth Stocks to Be Thankful for Well Into 2026 Posted On Nov 27, 2025 by Chris Markoch  It’s been a good year for strong growth stocks. Many stocks have had returns of over 100%. However, if you believe that past performance doesn’t predict future results, then these names may not be the best strong growth stocks to own in 2026. Table of ContentsStrong Growth Stocks: NVIDIA Strong Growth Stocks : Eli Lilly Strong Growth Stocks: Freeport-McMoRan Conclusion A better idea may be to look at the next tier of stocks. These stocks have still delivered growth in 2025. These may have not been the eye-popping gains of a stock like Palantir Technologies Inc. (NASDAQ: PLTR). But they may have a better valuation, and analysts project strong earnings growth in 2026. These are stocks that you would have been thankful to own in 2025. More importantly, they’ll continue to be strong growth stocks in 2026. Whether you’re a buy-and-hold investor or a swing trader, you’ll be off to a good start in the new year by having a position in these stocks. Strong Growth Stocks: NVIDIA NVIDIA Corp. (NASDAQ: NVDA) has had a good year by any measure. The company has everything that investors want. It shows strong year-over-year growth in revenue, earnings, and margins. But with NVDA stock “only” up 34.5% in 2025, some investors suggest that the company’s best days are behind it. In this analyst’s opinion, their concerns are based on a faulty premise. As NVIDIA’s recent quarter showed, the company has a backlog for quarters to come. Sure, competitors are entering the fray. But that’s largely because the pie is getting bigger, not because NVIDIA is losing its share of that pie. It’s still the undisputed leader in the artificial intelligence (AI) buildout that’s still in its infancy. Analysts forecast 46% earnings growth in the next 12 months, which goes a long way to dispelling any concerns about the company’s forward P/E ratio of around 64x. That’s why NVDA stock is one stock to be thankful to own now and into the future. Strong Growth Stocks : Eli Lilly Eli Lilly & Co. (NYSE: LLY)is up more than 42% in 2025 as the company has vaulted into the lead in the weight loss drug market. The company has committed over $50 billion into its global manufacturing footprint to ensure it maintains the lead in this critical market. But there’s more to the LLY stock story to keep it in this category of strong growth stocks for years to come. The company’s oral version of its GLP-1 drug just moved out of Phase 3 trials. This will be a game-changer that will allow the company to press its advantage in this market. Lilly also has a deep pipeline that includes many oncology drugs that will likely become available in the next few years. Analysts are forecasting 32% earnings growth in the next 12 months. And despite the fact that it trades for over $1,100 per share as of November 26, several analysts believe it can run much higher. In fact, on November 24, analysts from Bernstein gave LLY stock a $1,300 price target. Strong Growth Stocks: Freeport-McMoRan Gold has been one of the best-performing asset classes in 2025. That’s one reason to consider a mining stock like Freeport-McMoran Inc. (NYSE: FCX). A better one, however, is the expected growth in copper. Demand for copper is a narrative that’s been delayed, but it still exists. Copper will be needed to build the AI infrastructure. And that’s not to mention its utility in electric vehicles and the updating of our aging electric grid. Freeport-McMoRan is one of the leading copper miners in the world. FCX stock is only up about 11% in 2025, and analysts are only forecasting about 10% upside. That wouldn’t seem to qualify as strong growth. However, it’s just as likely that analysts aren’t accounting for the potential explosive leap in copper prices. Conclusion NVIDIA, Eli Lilly, and Freeport-McMoRan are three strong growth stocks for 2026. But there could be several more names that can be added to the list. For this list, I used a stock screener to identify stocks that were expected to grow earnings by at least 20% over the next 12 months. Earnings growth is one of the most accurate predictors of future stock price performance. It’s a good reminder to investors that you need to have your own signals that help you filter out the noise that exists during volatile times. This message is a PAID ADVERTISEMENT for Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) from Market Jar Media Inc. StockEarnings, Inc. has received a fixed fee of $4000 from Market Jar Media Inc for multiple Dedicated Email Sends, Newsletter Sponsorships and SMS Sends between Dec 01, 2025 and Dec 05, 2025. Other than the compensation received for this advertisement sent to subscribers, StockEarnings and its principals are not affiliated with either Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) or Market Jar Media Inc. StockEarnings and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither StockEarnings nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from StockEarnings to buy or sell any security. StockEarnings has not evaluated the accuracy of any claims made in this advertisement. StockEarnings recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) on TradingWhisperer website for additional information about the relationship between Market Jar Media Inc and Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL).Your privacy is very important to us, if you wish to be excluded from future notices, do not reply to this message. Instead, please click Unsubscribe. StockEarnings, Inc 33 SE 4th St, Suite 100, Boca Raton, FL 33432 USA W: 877.6.STOCKS StockEarnings.com |
